logo-loader
Iofina PLC

Iodine producer Iofina delivers record full year

The iodine and chemicals manufacturer reported record earnings (EBITDA) for the year ended 31 December 2018 of US$2.6mln, 89% higher than the prior year

Iodine element
Iofina had continued to break records in its current year, reporting its best ever first quarter iodine production of 134.4 MT in mid-April

Iofina PLC (LON:IOF) delivered a “record year” in 2018 on the back of increased iodine production at its IOsorb plants in Oklahoma.

The iodine and chemicals manufacturer reported record earnings (EBITDA) for the year ended 31 December 2018 of US$2.6mln, 89% higher than the prior year, while revenues climbed 15% to US$24mln.

WATCH: Iofina highlights record production and earnings for 2018as iodine prices strength

Pre-tax losses, meanwhile, had narrowed by 85% to US$1.4mln. The group also ended the year with a cash balance of US$4.5mln, up 32% year-on-year.

The company said it had produced its highest ever amount of crystalline iodine, which rang in at 588.8 metric tonnes (MT) compared to 503 MT in 2017.

Iofina had continued to break records in its current year, reporting its best ever first quarter iodine production of 134.4 MT in mid-April.

Plans for an eighth production site were also under way, with construction expected to begin later this year.

Dr Tom Becker, Iofina’s president and chief executive, added that prices in the iodine market had continued to “move in a positive direction”, with more growth expected throughout the rest of the year.

“Over the last few years, by executing cost savings plans, prudent growth, and investing in new products, the group has turned itself around and is performing at its highest level to date.”

Iodine, which Iofina extracts from brine produced by onshore oil wells, is an element that has a wide range of uses including as a disinfectant and as a dye pigment.

“More of the same please”, says broker

In a note to clients, analysts at Iofina’s ‘house’ broker finnCap said the company’s “laser focus” on costs and efficiency improvements “should continue to pay dividends”, with the projected increase in iodine prices likely to amplify the benefits.

The broker added that Iofina’s recently established cannabinoid division, IofinaEX, was “a natural fit” as its current iodine production used many of the same processes required to extract the cannabis-derived chemicals.

“Iofina also has operations in Montana, Colorado and Kentucky, the top three regions for hemp production in the US. Diversification into synergistic, high-growth new areas can be no bad thing as long as it doesn’t distract from the progress being made in its core Resource and Chemical divisions”.

finnCap has Iofina pegged with a 34p target price.

In afternoon trading, shares were down 2.1% to 16.15p on Wednesday.

--Updates for video link and share price--

Quick facts: Iofina PLC

Price: £0.28

Market: LSE
Market Cap: £54.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Iofina PLC named herein, including the promotion by the Company of Iofina PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

E-Therapeutics signs deal with top five global pharma company for new project

Headlines from the Proactive UK newsroom. E-therapeutics (LON:ETX) is to work with a global, top five pharmaceutical company on a project related to neurodegenerative diseases such as Parkinson's, Alzheimer's and Huntington's. Results and the IP of the project will remain the property of...

on 13/8/19

2 min read